Current immunotherapy guidelines are based primarily on patients’ PD-L1 levels on the primary tumor or recent tumor mutation burden (TMB) levels to determine whether they are eligible for PD-1/PD-L1 inhibitor therapy [34]. Here, CD274 is linked to neoplasm.